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Abstract
Introduction: MYB is highly expressed in estrogen receptor positive (ER + ve) breast tumours and tumour cell
lines. We recently demonstrated that MYB is essential for the proliferation of ER + ve breast cancer cells, and have
now investigated its role in mammary epithelial differentiation.
Methods: MCF-7 breast cancer cells were treated with sodium butyrate, vitamin E succinate or 12-O-
tetradecanoylphorbol-13-acetate to induce differentiation as measured by Nile Red staining of lipid droplets and b-
casein expression. The non-tumorigenic murine mammary epithelial cell (MEC) line, HC11, was induced to
differentiate with lactogenic hormones. MYB levels were manipulated by inducible lentiviral shRNA-mediated
knockdown and retroviral overexpression.
Results: We found that MYB expression decreases following chemically-induced differentiation of the human
breast cancer cell line MCF-7, and hormonally-induced differentiation of a non-tumorigenic murine mammary
epithelial cell (MEC) line, HC11. We also found that shRNA-mediated MYB knockdown initiated differentiation of
breast cancer cells, and greatly sensitised them to the differentiative and pro-apoptotic effects of differentiation-
inducing agents (DIAs). Sensitisation to the pro-apoptotic effects DIAs is mediated by decreased expression of BCL2,
which we show here is a direct MYB target in breast cancer cells. Conversely, enforced expression of MYB resulted
in the cells remaining in an undifferentiated state, with concomitant suppression of apoptosis, in the presence of
DIAs.
Conclusions: Taken together, these data imply that MYB function is critical in regulating the balance between
proliferation, differentiation, and apoptosis in MECs. Moreover, our findings suggest MYB may be a viable
therapeutic target in breast cancer and suggest specific approaches for exploiting this possibility.
Introduction
There is a critical balance between proliferation, differ-
entiation, and apoptosis in the cellular composition of
every tissue. In the hematopoietic system, MYB clearly
plays a role in maintaining this balance. MYB is essential
for hematopoiesis [1], is highly expressed in immature
hematopoietic cells and its expression is down-regulated
upon differentiation [2,3]. Moreover, enforced expres-
sion of normal and activated forms of MYB can sup-
press differentiation and maintain proliferation of
hematopoietic cells [4-6].
For these reasons, most work on MYB has focused on
its role in normal and leukemic hematopoiesis. However,
there is increasing evidence for a role of MYB in colonic
epithelial cell differentiation and homeostasis, and nota-
bly, in colon cancer [7]. The pattern of MYB expression
in normal colonic crypts suggests that, similarly to the
hematopoietic system, expression is high in immature,
rapidly proliferating cells, and decreases with differentia-
tion and maturation [8,9], whereas reduced MYB activity
perturbs colonic epithelial proliferation, differentiation
and viability [8,9]. The involvement of MYB in epithelial
tumors was first suggested by the amplification of MYB
in certain colon carcinoma-derived cell lines [10], and by
its expression in a substantial proportion of tumors
[7,11]. Moreover MYB expression in colon tumors corre-
lates with poor clinical prognosis [12], and an important
transcriptional regulatory region of MYB is frequently
mutated in this disease [13,14]. Furthermore, MYB is
required for colon carcinoma cell proliferation [7,15],
and is down-regulated during differentiation of these
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suppress their differentiation [16].
By contrast, much less is known about the functions of
MYB in mammary epithelial cells. Nevertheless, it has
been shown that MYB is expressed at relatively high
levels in estrogen receptor (ER) positive breast cancers
and tumor cell lines [17]. Moreover we, and others [18]
have previously shown that MYB is a direct target of
estrogen/ER signaling, and that MYB expression in breast
cancer cells is regulated by transcriptional attenuation
within its first intron [19]. Importantly, we have also
recently shown that MYB is required for the proliferation
of ER positive, but not ER negative, breast cancer cell
lines [19], identifying for the first time a functional role
for MYB in breast cancer. In addition, Fang et al [20]
reported a prolactin-inducible association between MYB
and Stat5a, and that a number of Stat5a-responsive pro-
moters such as that of the CISH gene are further stimu-
lated by MYB. Their results suggested that MYB may act
as a coactivator for Stat5a, and also supported a prolifera-
tive function for MYB in human breast cancer.
To further understand the function of MYB in breast
cancer and in mammary epithelial cells (MECs) gener-
ally, we have now investigated its role in the differentia-
tion of these cells. Differentiation of human breast
cancer cell lines (MCF-7 and ZR-75-1) and non-tumori-
genic MEC (HC11) can be induced by chemical agents
or lactogenic hormones, respectively, and results in mor-
phological and molecular properties that are characteris-
tic of mature ductal epithelial cells. We have found that
mammary carcinoma cell lines in which MYB expression
was ‘knocked-down’ by shRNA show changes that indi-
cate differentiation has occurred in some of these cells.
Moreover, these MYB knock-down cells are more sensi-
tive to differentiation after exposure to low doses of dif-
ferentiation-inducing agents, and can be driven into
apoptosis with doses that would normally only induce
differentiation. Conversely, ectopic expression of MYB
suppressed differentiation and apoptosis induced by dif-
ferentiation-inducing agents (DIAs). Taken together, our
data show that MYB plays an important role in regulat-
ing the balance between proliferation, differentiation,
and apoptosis in both normal and malignant mammary
epithelial cells, and that this role is remarkably similar
to that it plays in hematopoietic and colonic epithelial
cells. Finally, our observation that DIAs and MYB inhi-
bition synergize in killing breast tumor cells suggests an




The breast cancer cell lines MCF-7 and ZR-75-1 were
cultured in DMEM (Invitrogen, Mount Waverley, Vic,
Australia) supplemented with 10% FBS, l-glutamine,
penicillin G, and streptomycin sulfate (All from GIBCO/
BRL, Grand Island, New York, USA). All cell lines were
maintained at 37°C in a humidified 5% carbon dioxide/
95% air incubator. Prior to reaching confluence, cells
were trypsinized with a 0.05% trypsin/0.53 mM EDTA
solution and resuspended in fresh growth medium
before plating onto a new growth surface.
Sodium butyrate, vitamin E succinate, and 12-O-tetra-
decanoylphorbol-13-acetate were purchased from Invi-
trogen (Mount Waverley, Vic, Australia).
HC11 cells were grown in Roswell Park Memorial
Institute medium (RPMI)-1640 (Invitrogen, Mount
Waverley, Vic, Australia) medium containing 10% FBS,
5 μg/ml insulin, and 10 ng/ml epidermal growth factor
(both from Sigma-Aldrich, Castle Hill, NSW, Australia).
Differentiation was induced three days after reaching
confluence in medium containing 5 μg/ml insulin, 1 μg/
ml hydrocortisone and 5 μg/ml prolactin (Sigma-
Aldrich, Castle Hill, NSW, Australia).
For lipid droplet staining, cells grown on glass cover
slips were rinsed twice with PBS and fixed for 20 min-
utes with PBS containing 4% paraformaldehyde at 20°C.
After another PBS rinse and staining for 15 minutes
with Nile Red and 4′,6-diamidino-2-phenylindole (DAPI)
(Sigma-Aldrich, Castle Hill, NSW, Australia), the cells
were PBS washed and mounted. Fluorescence imaging
was performed by using automated excitation and emis-
sion filter wheels of a Fluorescent AxioSkop 2 plus
Microscope (Carl Zeiss Pty Ltd, New South Wales, Aus-
tralia). For flow cytometric analysis, cells not grown on
glass cover slips were washed in PBS, and resuspended
in PBS containing 0.01% Nile Red for 15 minutes at 37°
C. After three washes in PBS, they were analyzed by
flow cytometry using a FACS Calibur instrument (Bec-
ton Dickinson, San Jose, CA, USA), and the primary
data were then processed using CellQuest software (Bec-
ton Dickinson, San Jose, CA, USA).
For siRNA transfection experiments, MCF-7 cells were
plated and transfected the following day with 100 nM of
BCL2 specific, or and control siRNAs (Dharmacon
Research, Lafayette, CO, USA) by using lipofectamine
2000 (Invitrogen, Mount Waverley, Vic, Australia).
Briefly, all transfections were performed in a mixture of
Opti-MEM and complete media without antibiotics, as
described previously [21]. The transfection incubation
time for siRNA/lipofectamine 2,000 complexes was 24
hours.
Chromatin immunoprecipitation assay
MCF-7 cells were grown to 95% confluence in phenol-red-
free DMEM supplemented with 10% charcoal-stripped
FBS for 72 hours; at which time, 10 nM b-estradiol was
added for 12 hours. Chromatin immunoprecipitation
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using rabbit immunoglobulin (Ig) G (Sigma, Castle Hill,
NSW, Australia) and 1.1 anti-Myb/5.1 anti-Myb or 1.1
anti-Myb/Thelma anti-Myb monoclonal antibodies [23].
The resultant samples were used as real-time PCR tem-
plates to quantify binding of MYB to the various regions
of BCL2, MYC or GAPDH. Primer sequences used in the
PCR were: Myb binding sites (MBS)1F5 ′-GCTCAGAG-
GAGGGCTCTTTC-3′,M B S1R5 ′-TTTCTCCTCCTC
CTGGTCCT-3′, MBS 2F5 ′-CCCGCCTCTTCACCTTT-
CAG-3′, MBS 2R5 ′-CAATGGCACTTCAAGTCCCGA,
MBS 3 F-5′-GGTCAGGTGGACCACAGGT- 3′, MBS 3R
5′-GTCCAAGAATGCAAAGCACA-3′, MBS 4F5 ′-
CACAGCGCCAACAGAACTAC-3′, MBS 4R5 ′-ACAGG
CCAGATGCCAGATAC-3′, MYC F5 ′-GCCTGCGAT-
GATTTATACTCACAG-3′, MYC R5 ′-CGGAGAT-
TAGCGAGAGAGGATC-3′, GAPDH F5 ′-ATCAATGGA
AATCCCATCACCATCT-3′, GAPDH R5 ′-GGTTTTTC
TAGACGGCAGGTCAG-3′, Upstream Control F 5′-
GCAGGTGCTCAACAGATGAA-3′, Upstream Control R
5′-GGGATTGCCTTACAGGTGAA-3′.
TUNEL
Apoptosis-induced nuclear DNA fragmentation was
detected using the TMR Red In Situ Cell Death Detec-
tion Kit (Roche Diagnostics Corp, Indianapolis, IN,
USA) following the manufacturer’s protocol. Briefly,
24 hours after DIA treatment, cells grown on glass
cover slips were fixed. This was followed by incuba-
tion in terminal deoxynucleotidyl transferase (TdT)-
mediated dUTP nick end labeling (TUNEL) reaction
mix for 60 minutes at 37°C. Slides were washed three
times in PBS/Triton X-100/BSA (0.3%) and visualized
on a fluorescent microscope. Cells not grown on glass
cover slips were washed in PBS, and resuspended in
PBS and TUNEL reaction mix for 60 minutes at 37°C.
Cells were washed three times in PBS, and analysed by
flow cytometry on the FACS Calibur as described
earlier.
Quantitative RT-PCR
T o t a lR N Aw a sp r e p a r e db yu s i n gaR N e a s yM i n i K i t
(Qiagen, Valencia, CA, USA) according to the manufac-
turer’s instructions. One microgram of total RNA was
reverse transcribed in a total of 20 μlb yu s i n gS u p e r -
Script III (Invitrogen, Carlsbad, CA, USA). The resulting
cDNA was then diluted to a total volume of 100 μl with
sterile water. Each real-time PCR consisted of 1 μlo f
diluted reverse transcriptase product, iQ SYBR Green
Supermix (Bio-Rad, Hercules, CA, USA), and 50 nM
forward and reverse primers (see below). Reactions were
carried out on a RotorGene 3000 (Corbett Research,
Sydney, NSW, Australia) at 95°C for 10 minutes,
followed by 40 cycles of 95°C for 20 seconds, 56°C for
15 seconds, and 72°C for 20 seconds. Fluorescence mea-
surements analyzed by using the RotorGene 3000 soft-
ware. The fold-change expression of each gene was
calculated by using the ΔΔCT method, with cyclophilin
A as an internal control. Primers used for real-time PCR
were: MYB F, 5′-GCCAATTATCTCCCGAATCGA-3′;
MYB R, 5′-ACCAACGTTTCGGACCGT A-3′; ß-casein
F, 5′-CCCTCAAATCCCAAAACTCA-3′; ß-casein R, 5′-
GAGCAGAAGGGCTTGAACAG-3′; BCL2 F, 5′-
GTTCGGTGGGGTCATGTGTGTGGAGAGCG-3′;
BCL2 R5 ′-TAGCTGATTCGACGTTTTGCCTGA-3′;
Cyclophilin AF ,5 ′-GGCAAATGCTGGACCCAACA-
CAAA-3′; Cyclophilin AR ,5 ′-CTAGGCATGGGAGG-
GAACAAGGAA-3′.
Western blotting
Western blot analysis was conducted as described pre-
viously [24]. Briefly, extracts prepared in SDS loading
buffer were resolved in SDS/10% PAGE gels and trans-
ferred to PVDF membranes. These were incubated over-
night in the presence of anti-c-Myb antibody 1.1 [25]
and were developed by using ECL western blotting sub-
strates (Pierce Biotechnology, Rockford, IL, USA).
Results
Characterization of, and MYB expression during, the
differentiation of human mammary carcinoma cell lines
We first characterized the differentiation of MCF-7 (and
ZR-75-1; data not shown) cells using several reported
markers of this process. A number of compounds are
capable inducing differentiation in breast cancer cells,
such as sodium butyrate (NaBu), vitamin E succinate
(VES) or 12-O-tetradecanoylphorbol-13-acetate (TPA)
[26,27]. We examined the formation of lipid droplets as
an indicator of breast cancer cell differentiation [28]
using the fluorescent dye Nile Red in combination with
fluorescence microscopy or flow cytometry [29]. Vehi-
cle-only treated MCF-7 cells expressed only minimal
numbers of detectable lipid vacuoles when stained with
Nile Red (Figures 1a and 1b). By contrast, there was a
dose-dependent increase in the accumulation of lipid
droplets in the cytoplasm of the cells treated with NaBu
for 72 hours, and in cells treated with VES and TPA
[see Additional File 1].
As mammary epithelial cells undergo differentiation
t h e r ei sa ni n c r e a s ei nt h et r a n s c r i p t i o no ft h eg e n e
encoding the milk protein ß-casein [26]; as such, this
can be used as a molecular marker for differentiation.
Indeed, quantitative RT-PCR showed that ß-casein mes-
sage was significantly increased after treatment of MCF-
7 cells with increasing concentrations of DIAs for
72 hours (Figure 1c).
Previous studies have shown that differentiation of a
number of different cell types, notably hematopoietic
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ciated with a reduction in MYB expression. Therefore,
we asked whether the level of MYB would also be
reduced when mammary carcinoma cells underwent
differentiation. The MYB message was, as expected,
readily detectable in control MCF-7 cells by
quantitative RT-PCR, but treatment with increasing
concentrations of NaBu for 72 hours induced a dose-
dependent decrease in the level of MYB message
(Figure 1d). Western blot analysis of total cell lysates
showed a corresponding profile for the MYB protein
(Figure 1e).
Figure 1 Differentiation induction and cells treated with the differentiation-inducing agent NaBu. (a) MCF-7 cells were grown on glass
cover slips and treated with increasing amounts of sodium butyrate (NaBu), as indicated, for 72 hours. Morphological changes were evaluated
by fluorescent microscopy (×63). Induction of biochemical differentiation was determined by using Nile Red stain for lipid vesicles in cells (red).
Nuclear DNA was stained with 4’,6-diamidino-2-phenylindole (DAPI) (blue). (b) Quantitative analysis of lipid induction. MCF-7 cells, as above, were
stained with Nile Red and analyzed by flow cytometry as described in the Materials and methods. Standard deviations are shown as error bars (n
= 6). (c) Quantitative (Q) PCR of ß-casein mRNA expression following treatment with increasing doses of NaBu. The induction of ß-casein is
normalized against that seen in untreated cells. (d) Q-PCR of MYB mRNA from MCF-7. MCF-7 cells treated with the increasing dosage of NaBu
show a dose dependent decrease in expression of MYB mRNA. Data from (c) and (d) represent mean values (n = 6), and standard deviations are
shown as error bars. All Q-PCR data were normalized against cyclophilin A controls. (e) Western blot analysis of MYB from total cell lysates as
above. A ß-tubulin loading control is also shown. Results are indicative of two independent experiments.
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tumorigenic mammary epithelial cells
HC11 is an immortalized line of non-transformed mam-
mary epithelial cells, which originated from mid-preg-
nant mouse mammary gland tissue, and has retained
important characteristics of normal mammary epithelial
cells [30]. Following stimulation with lactogenic hor-
mones, these cells differentiate, synthesize ß-casein, and
form blister-like structures, called ‘domes’ that are
believed to result from fluid secretions. We first con-
firmed that HC11 MECs could undergo differentiation
in the presence of lactogenic hormones, as monitored
by the presence of lipid droplets detected by Nile Red
(Figures 2a and 2c), the formation of domes (Figure 2b),
and the induction of ß-casein expression (data not
shown). In the course of such experiments, cell differen-
tiation occurred progressively after removal of epidermal
growth factor (EGF) for 24 hours and the subsequent
addition of lactogenic hormones over seven days. Quan-
titative RT-PCR and western blot analysis demonstrated
a decrease of the steady state levels of MYB mRNA and
protein, respectively, as these cells underwent differen-
tiation (Figures 2d and 2e). These data suggest that the
reduction in MYB levels is part of the normal pathway
of differentiation of mammary epithelial cells, and vali-
date the use of mammary carcinoma cell lines and
MECs as models to study the role of MYB in this
process.
MYB knockdown promotes differentiation of mammary
carcinoma cells
We have previously used a doxycycline (Dox)-inducible
lentiviral siRNA system targeting MYB to show that
MYB is required for the proliferation of ER positive cell
lines [19]. To examine the effect of MYB knockdown on
differentiation, MCF-7 cells stably transduced with this
vector, or appropriate controls, were treated with Dox
for 72 hours. The cells were then stained for lipid dro-
plet accumulation using Nile Red. Approximately 35%
of MYB knockdown cells stained positively for lipid dro-
plet accumulation in contrast to approximately 20% of
control cells [see Additional file 2]. This is a modest, yet
statistically significant (Student’stt e s t ,n =6 ,P <0 . 0 5 ) ,
increase. It should be noted that the intensity of Nile
Red staining was greater in the MYB knockdown cells,
and the number of droplets/cell and droplet size in the
MYB knockdown cells were greater than those seen in
the control cells as visualized by fluorescence micro-
scopy [see Figure S2A in Additional file 2]. In addition,
ß-casein mRNA levels rose by approximately 3 fold fol-
lowing MYB knockdown [see Figure S2C in Additional
file 2]. These experiments were repeated using ZR-75-1
cells, and a similar result was observed [see Additional
file 3]. These data suggest that MYB knockdown induces
breast tumor cells to initiate the process of differentia-
tion in the absence of DIAs, albeit with limited
efficiency.
Synergy between DIA treatment and MYB knockdown
As MYB knockdown in mammary carcinoma cells
resulted in only a limited amount of differentiation, we
next asked whether MYB knockdown was able to act in
a synergistic manner with DIAs. MYB knockdown
MCF-7 cells, and appropriate controls, were treated
with or without Dox for 24 hours, and then treated
with NaBu or VES for a further 72 hours. Staining for
lipid droplet accumulation treated with or without Dox
(Figures 3a and 3b) showed that the effect of MYB
knockdown coupled with the lowest concentration of
VES or NaBu caused differentiation comparable with
that seen only with the highest concentration of DIAs
used alone (Figure 1a). Strikingly, when MYB knock-
down cells were treated with the higher concentration
of the DIA, complete cell death, rather than differentia-
tion, was observed (Figures 3a and 3b). Similarly-treated
cells were then assayed by TUNEL after 24 hours of
exposure to DIA. A high percentage of these cells
appeared apoptotic on microscopic inspection, and
FACS analysis of these cells showed that approximately
80% of had undergone apoptosis (Figure 3c); in contrast
all control treatments resulted in a background level of
10 to 20% of TUNEL staining. Similar results were
obtained using MCF-7 cells treated with TPA, and with
ZR-75-1 cells treated with all three DIAs [see Addi-
tional file 4] (data not shown). Thus these data show
that MYB knockdown sensitizes mammary carcinoma
cells to differentiation and, at high concentrations of
DIA, to apoptotic death.
BCL2 is regulated by MYB in breast cancer cells
T h ed a t aa b o v es u g g e s tt h a tMYB m a yb ep r o t e c t i n g
mammary epithelial cells against differentiation-asso-
ciated apoptosis. BCL2 suppresses apoptosis via its
interaction with other, pro-apoptotic members of the
BCL2 family, and, moreover, several previous studies
have shown that MYB regulates BCL2 gene expression
in hematopoietic cells and in colonic epithelial cells
[8,9,31]. We therefore examined BCL2 levels by quanti-
tative RT-PCR in MCF-7 cells that had been treated
with increasing concentrations of NaBu. As the MYB
mRNA levels decreased (Figures 1d and 1e), there was a
corresponding down-regulation of BCL2 mRNA (Figure
4a). We also measured BCL2 mRNA levels in the MYB
knockdown MCF-7 cells, which revealed that induction
of MYB shRNA resulted in a 65 to 70% reduction com-
pared with controls (Figure 4b). Conversely,
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Page 5 of 17Figure 2 Myb expression during confluence/hormone-induced differentiation of HC11 cells.H C 1 1w e r ep r o l i f e r a t i n g( D a y1 ) ,g r o w nt o
confluence (Day 2), and then differentiated by removing epidermal growth factor (EGF) for 24 hours (Day 3), followed by addition of
differentiation medium containing lactogenic hormones (Days 4 to 9). (a) HC11 cells grown on glass cover slips were stained for DNA (4’,6-
diamidino-2-phenylindole [DAPI]; blue), lipid vesicles (Nile Red; red), and viewed under fluorescence microscopy at Day 1 and Day 9. (b) HC11
cells were grown in 24-well dishes, and induced to differentiate as described. Shown are light micrographs of confluent cells and ‘domes’
(arrow) which form in the presence of differentiation inducing medium. (c) Quantitative analysis of Nile Red staining by flow cytometry. HC11
cells were analyzed for lipid vesicle formation during the different stages of differentiation. (d) Quantitative PCR of MYB mRNA from HC11 cells
undergoing differentiation. HC11 cells were analyzed each day during the differentiation process. Standard deviation is represented by error bars.
(e) Western blot analysis of MYB protein from total cell lysates of HC11 cells during the differentiation process. A ß-tubulin loading control is also
shown. Results are indicative of two independent experiments.
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Page 6 of 17Figure 3 MYB knockdown sensitizes MCF-7 to differentiation-inducing agents. (a) Vitamin E succinate (VES) was used to treat MCF-7 cells
with a doxycycline (Dox)-inducible shRNA targeting MYB [19] MCF-7 cells grown on a glass coverslip, and treated with or without 5 mg/mL Dox
for 24 hours before exposure to VES for three days, were then stained with Nile Red (red) for lipid vesicles and 4’,6-diamidino-2-phenylindole
(DAPI) (blue) for DNA detection. (b) Sodium butyrate (NaBu) was used to treat MCF-7 cells with the Dox-inducible shRNA targeted against MYB,
as in (a). Results are indicative of at least two independent experiments. (c) Flow cytometric analysis of TUNEL staining for apoptotic cells. MCF-7
cells stably transfected with inducible shRNA treated for 24 hours with or without Dox, were grown in the presence or absence of 1 mM NaBu
for a further 24 hours, and were then assayed for apoptosis using TUNEL. Standard deviation is represented by error bars.
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Page 7 of 17Figure 4 Expression, MYB regulation and function of BCL2 in MCF-7 cells. (a) BCL2 expression in MCF-7 cells treated with increasing doses
sodium butyrate (NaBu). After 72 hours of treatment, cells were harvested and the mRNA was analyzed for expression of BCL2 by quantitative
(Q) PCR. (b) MCF-7 cells stably transduced with an inducible MYB shRNA vector were grown in the presence of doxycycline (Dox) for three days,
after which BCL2 was analyzed by Q-PCR. Standard deviation is represented by error bars. (c) A schematic of the BCL2 gene (not to scale)
showing the relative locations of the primers (MBS-1-4) used for ChIP assays. (d) Q-PCR of MCF-7 cells assessed by ChIP assays using anti-MYB
Ab. Rabbit IgG was used as a negative control. MYC is used as a positive control, and GAPDH and an upstream primer set are used as negative
controls. (e) Western blot analysis of BCL2 knockdown by four siRNAs (#1-4), parental cells, and control siRNA. MCF-7 s were transiently treated
with the siRNAs and at 24 hours, assessment of their ability to reduce BCL2 was undertaken. A ß-tubulin loading control is also shown. Results
are indicative of two independent experiments. (f) MCF-7 cells treated with four independent BCL2 siRNAs were grown for 24 hours with 0, 0.1,
or 1 mM NaBu as indicated. TUNEL assays were analyzed by flow cytometry to quantify the number of apoptotic cells. Standard deviation is
represented by error bars.
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levels of BCL2 protein (Figure 5a).
Although BCL2 is a direct target of MYB in T and
myeloid cells [32-34] (Zhao et al:D e f i n i n gt h eM Y B
Transcriptional Program by Genome-Wide Chromatin
Occupancy and Expression Analyses, submitted) this has
not been shown in other cell types. To determine
whether MYB acts directly on the BCL2 gene in breast
cancer cells, we performed ChIP assays using MCF-7
cells. Potential MBS in BCL2 promoters 1 and 2 were
identified based on binding sites previously mapped in
other cell types [34,35] in conjunction with the estab-
lished consensus sequence YAACN(G/T) for MYB pro-
tein binding [36,37]. Additional sites examined
corresponded to those detected by ChIP-Seq in murine
myeloid cells (Zhao et al, Defining the MYB Transcrip-
tional Program by Genome-Wide Chromatin Occupancy
and Expression Analyses, submitted), which are located
within intron 2 and downstream of exon 3 (Figure 4c).
Following immunoprecipitation of chromatin from
Figure 5 MYB overexpression in MCF-7 cells prevents differentiation-inducing agent-induced differentiation and growth arrest. (a)
MCF-7 cells were stably transduced with empty pMYS-IRES-GFP vector, or vectors encoding HA-tagged WT-or truncated, activated CT3-MYB.
Western blotting with anti-MYB Ab and anti-HA Ab confirmed the expression of exogenous, HA-tagged MYB proteins. Note that the anti-MYB
antibody used does not detect CT3-MYB. The Western blot was also probed for BCL2 expression (see text); a ß-tubulin loading control is also
shown. (b) MYB overexpression blocks lipid accumulation associated with differentiation. Cells were treated with 0.5 mM or 1 mM sodium
butyrate (NaBu) for 72 hours, stained with Nile Red and analyzed by flow cytometry. (c) Proliferation of MCF-7 cells overexpressing WT or CT3-
MYB. MCF-7 cells overexpressing the WT or CT3-MYB, and controls, were grown in normal medium over seven days. (d) Proliferation of MCF-7
cells overexpressing the WT or CT3-MYB grown in medium containing 1 mM NaBu over seven days. In (c) and (d) cells were counted on days
one, three, five, and seven. Standard deviation is represented by error bars (n = 3).
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were detected with the primers for regions in BCL2 con-
taining the above-mentioned potential MBS. Quantita-
tive RT-PCR showed substantial enrichment for all four
regions and the positive control MYC, but not primers
corresponding to the GAPDH gene or a region 6 kb
upstream of BCL2, with the anti-Myb antibody (Figure
4d). These results demonstrate that endogenous MYB
binds in situ to the BCL2 gene and, combined with the
data of Figures 4a, b and 5a (see also below), imply that
MYB directly regulates BCL2 expression in mammary
carcinoma cells.
BCL2 knockdown sensitizes breast cancer cells to DIA-
induced apoptosis
The data presented above are all consistent with the
proposal that differentiation-associated apoptosis is due
in part to loss of BCL2 function. To further investigate
this hypothesis, siRNAs targeting BCL2 were transiently
transfected into MCF-7 cells, which were subsequently
treated with NaBu. BCL2 knockdown was verified by
western blot analysis (Figure 4e). When assayed for
apoptosis with TUNEL, BCL2 knockdown induced 60 to
70% apoptosis in the presence of a level (1 mM) of
NaBu that normally would only induce differentiation,
whereas only about 20% of cells were TUNEL positive
when treated with BCL2 siRNA alone (Figure 4f). Thus
BCL2 knockdown in MCF-7 cells resulted in similar
sensitivity to DIA-induced apoptosis to that seen when
MYB was knocked down using shRNA (Figure 3).
Enforced expression of MYB suppresses differentiation
and apoptosis of MECs
T of u r t h e re x a m i n et h er o l eo fMYB in the differentia-
tion of MECs, MCF-7 cells were stably transduced with
retroviral vectors expressing either wild type (WT)
MYB, a truncated, activated form of MYB (CT3) [38], or
the empty pMYs-IRES-GFP vector. Overexpression of
MYB was verified by western blot analysis (Figure 5a).
The cells were then treated for 72 hours with NaBu.
Although MYB overexpression had no effect on prolif-
eration of untreated cells (Figure 5c), Figure 5d shows
that overexpression of WT or CT3-MYB allowed the
cells to continue proliferating, and prevented differentia-
tion in the presence of NaBu (Figure 5b). As expected,
the parental and vector control cells ceased proliferating
and underwent differentiation as quantitated by Nile
Red staining. These data indicate that overexpression of
MYB is capable of preventing induced differentiation of
MCF-7 cells.
HC11 cells were also stably transduced with the MYB
retroviruses, and western blot analysis similarly showed
that these cells overexpressed WT or CT3-Myb (Figure
6a). When these cells were induced to differentiate with
Figure 6 MYB overexpression in HC11 cells prevents
differentiation and growth arrest. (a) HC11 cells were stably
transduced with empty vector, WT-MYB, or CT3-MYB, as in Figure 5.
Western blot with anti-MYB Ab and anti-HA Ab confirmed the
expression of exogenous and HA-tagged MYB proteins. A ß-tubulin
loading control is also shown. (b) MYB overexpression blocks lipid
accumulation associated with differentiation. Cells were stained with
Nile Red at the various stages of differentiation shown, and
analyzed by flow cytometry. Standard deviation is indicated by error
bars. (c) HC11 cells overexpressing WT or CT3-MYB continue to
proliferate in differentiation-inducing conditions. HC11 cells as
indicated were grown in complete media for two days, after which
epidermal growth factor (EGF) was removed for 24 hours and
subsequent lactogenic hormones were added to the medium each
day Standard deviation is indicated by error bars (n = 3).
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pressing cells showed markedly reduced staining with
Nile Red compared with controls (Figure 6b), and did
not form the domes associated with differentiation (data
not shown). The enforced expression of Myb also
allowed these cells to continue proliferating in the pre-
sence of the lactogenic hormones (Figure 6c); interest-
ingly, proliferation was able to continue in the absence
of EGF, although the rate of proliferation was less than
that seen in its presence (data not shown).
Overexpression of MYB protects mammary carcinoma cell
lines from DIA-induced apoptosis
A st h ed a t aa b o v es h owed that enforced MYB expres-
sion is able to prevent differentiation of MECs, and the
data of Figure 3 showed that knockdown of MYB results
in DIA-induced apoptosis, we asked whether ectopic/
overexpression of MYB could also protect breast tumor
cells against DIA-induced apoptosis. Although the levels
of DIAs used in the experiments described above did
n o ti n d u c eas i g n i f i c a n td e g r e eo fa p o p t o s i s ,o t h e r
reports indicate that higher levels of some of these com-
pounds can do so [39-41]. First, a dose-response assay
of DIAs on MCF-7 cells was carried out to determine
the level of NaBu required to induce apoptosis in MCF-
7 cells at 24 hours (Figure 7a). The MCF-7 WT-MYB
and CT3-MYB overexpressing cells, described above,
were then treated with apoptosis-inducing levels of each
DIA and assayed with TUNEL. Figure 7b shows that
overexpression MYB substantially reduced the propor-
tion of cells undergoing apoptosis at the higher concen-
trations of NaBu. Similar results were obtained with two
other DIAs, VES and TPA (data not shown).
Given that MYB overexpression results in an increase
in the level of BCL2 (Figure 5a), and protects MCF-7 s
from differentiation-induced apoptosis (Figure 7b), we
next sought to investigate whether BCL2 was required
for this activity of MYB. MCF-7 cells overexpressing
WT MYB, or transduced with the empty vector only,
were transiently transfected with two of the siRNAs tar-
geting BCL2 used previously (Figure 4). These cells were
then treated with 0 or 100 mM NaBu for 24 hours
before TUNEL assay for apoptotic cells. Figure 7c shows
that the protective effect of MYB overexpression on
cells treated with high levels of NaBu is almost comple-
tely abolished when BCL2 expression is suppressed.
Anti-estrogen and DIA treatments synergize to induce
differentiation and apoptosis of breast cancer cells
As mentioned above, MYB expression is directly and posi-
tively regulated by estrogen/ER signaling in MCF-7 and
other ER positive breast cancer cells [18,19]. We therefore
predicted that a pure estrogen antagonist (as distinct to
selective estrogen response modifiers such as tamoxifen)
might synergize with DIAs in inducing differentiation and
apoptosis of such cells. That is, we reasoned that down-
modulation of MYB resulting from estrogen antagonist
treatment would mimic that resulting from shRNA-
mediated knockdown. We therefore treated MCF-7 cells
with the DIA NaBu, the estrogen antagonist fulvestrant/
ICI182780, or both. Reduction of MYB expression by ful-
vestrant was confirmed by western blotting (Figure 8a).
Figure 8b shows that treatment with 0.5 mM NaBu or
with fulvestrant alone had little effect, and that as expected
1 mM NaBu induced differentiation but little apoptosis.
However, the combination of fulvestrant and 0.5 mM
NaBu induced substantial differentiation and importantly,
combination with 1 mM NaBu induced extensive apopto-
sis (Figure 8c). These data are similar to those we obtained
by combining shRNA-reduced MYB knockdown with DIA
treatment of MCF-7 cells (Figure 3).
Discussion
MYB regulation of mammary epithelial cell differentiation
The studies reported here have shown that MYB has an
important role in the control of MEC differentiation
and in the resistance of mammary carcinoma cells to
apoptosis. As we will discuss further, this role appears
to parallel that played by MYB in other cell systems
where MYB expression and function has been exten-
sively characterized - hematopoietic cells and colonic
epithelium [4-6,42]. We have confirmed that, like some
other cancer cells, mammary carcinoma cells can be
induced to differentiate and shown that MYB expression
decreases during this process. Similarly to the haemo-
poietic and colonic epithelial cell systems, decreased
MYB expression on differentiation is not limited to
tumor cell lines, as we have shown here for the non-
tumorigenic murine MEC line HC11.
A functional role for MYB in MEC differentiation is
implied by the effects of MYB knockdown on breast
cancer cell lines. Although a small degree of differentia-
tion was observed with an inducible MYB shRNA alone,
a more dramatic effect was apparent from the synergy
between MYB knockdown and (otherwise) marginally-
effective concentrations of DIAs, which resulted in
essentially complete differentiation. Conversely, enforced
MYB expression was able to block differentiation of
both carcinoma cells and non-tumorigenic HC11 cells,
again strikingly paralleling the activities of MYB in other
cell systems [6,16,43-45].
How MYB exerts its effects on differentiation in this
system is unknown. One might suspect that the G1
phase growth arrest that accompanies MYB knock-
down [19] and differentiation [27] [see Additional file
1] in mammary carcinoma cells may be important but
is unlikely to be sufficient, because only limited differ-
entiation was observed following MYB knockdown
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known about the transcriptional network that regulates
differentiation of MECs than in other systems such as
hematopoiesis. Thus, our findings suggest that studies
to identify MYB t a r g e tg e n e si nM E C sw o u l ds h e d
light not only on MYB function but also on MEC dif-
ferentiation per se. Such targets may be directly bound
by MYB (as shown here for BCL2) or as in the case of
Stat5a-regulated genes, by MYB functioning as a co-
activator [20].
MYB and apoptosis of mammary carcinoma cells
When MYB knockdown was induced in the presence
of DIAs at concentrations that normally induce
efficient differentiation but little cell death, apoptosis
in over 80% of cells resulted. This was true for all
three DIAs (NaBu, VES and TPA) and both cell lines
tested, implying that it is a general phenomenon and
not the property of one agent or cell line. In any case
this observation, taken together with the ability of
DIAs at higher concentrations to induce apoptosis by
themselves [41,46,47] (Figure 7a), and the ability of
MYB overexpression to protect against apoptosis, sup-
ports the following model .W es u g g e s tt h a tD I A s
induce pro-apoptotic signals that, at normal differen-
tiation-inducing concentrations, are countered by
MYB activity, whereas either increased DIA concen-
trations and hence stronger apoptotic signaling, or
Figure 7 MYB overexpression prevents differentiation-inducing agents-induced apoptosis in a BCL2-dependent manner. (a) MCF-7 cells
were treated with the indicated doses of sodium butyrate (NaBu) for 24 hours before being assayed with TUNEL, which was quantified by flow
cytometry. (b) MCF-7 cells stably overexpressing WT-MYB, CT3-MYB, or vector, or control parental, were treated with 10 mM or 100 mM NaBu for
24 hours prior to TUNEL assay. (c) MCF-7 cells stably overexpressing WT MYB, or control vector, were transiently transfected with siRNAs
targeting BCL2. They were then treated with 0 or 100 mM NaBu for 24 hours before being assayed with TUNEL. Standard deviation is
represented by error bars (n = 6).
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Page 12 of 17Figure 8 Fulvestrant synergizes with NaBu to enhance the DIA sensitivity of MCF-7 cells. (a) Western blot analysis of MYB expression in
MCF-7 cells treated with fulvestrant or sodium butyrate (NaBu), alone or in combination, as indicated. (The combination of fulvestrant with 1
mM NaBu is not included because of extensive cell loss due to apoptosis. A ß-tubulin loading control is also shown. (b) MCF-7 cells grown on
glass slides were treated with fulvestrant alone or in combination with 0.5 mM or 1 mM NaBu for 72 hours. The cells were then stained with
Nile Red (red) for lipid vesicles and 4’,6-diamidino-2-phenylindole (DAPI) (blue) for DNA. (c) Apoptosis and (d) lipid accumulation were detected
by TUNEL assay and Nile Red staining, respectively, and quantitated by flow cytometry standard deviation is represented by error bars (n = 3).
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increased MYB expression overcomes the pro-apopto-
tic activity of higher DIA concentrations.
Our data and this model raise the question of what
the apoptotic signals induced by DIAs are, and how
MYB protects against them. NaBu has histone deactety-
lase inhibitor (HDI) activity [48], and indeed our unpub-
lished data show that the HDI suberoylanilide
hydroxamic acid (SAHA/Vorinistat) also acts as a DIA
in our system. Several mechanisms have been reported
for apoptosis induction by HDIs [49], including
enhanced expression of pro-apoptotic BH3-only proteins
[50]. Furthermore, VES has also been reported to trigger
the intrinsic apoptotic pathway, in this case via activa-
tion of Bax [51,52]. It is interesting to note that MCF-7
cells are known to be deficient in the apoptotic ‘execu-
tioner’ caspase 3 [53]. However, further work is needed
to define the mechanism of DIA-induced apoptosis of
breast cancer cells.
BCL2 suppresses apoptosis via the intrinsic pathway,
and thus regulation of BCL2 is a plausible mechanism
for the anti-apoptotic function of MYB in mammary
carcinoma cells. Indeed we have shown here that BCL2,
ak n o w nMYB target gene in other cell types, is directly
regulated by MYB in breast cancer cells, and have iden-
tified multiple MBS within the BCL2 gene. Moreover we
have shown that BCL2 is necessary for the ability of
MYB to protect such cells against DIA-induced
apoptosis.
A common role for MYB in multiple tissues and cancers?
As briefly reviewed in the Introduction, and more exten-
sively elsewhere [4-6], MYB is essential for the prolifera-
tion of multiple cancer and normal cell types, including
haemopoietic, colonic and mammary epithelial. Simi-
larly, with the data presented in this report, there is now
strong evidence that MYB can antagonize differentiation
in all three cell systems. MYB is also involved in vascu-
lar smooth muscle cell proliferation [54] and there are
reports of MYB down-regulation during differentiation
in this system too [55]. Moreover, c-myb expression in
developing and adult mice has been characterized using
in situ hybridization and correlated with stage-specific
differentiation and mitotic activity [56].
MYB can also suppress apoptosis in the hematopoietic
and colonic epithelial systems [8,32,57], and, as reported
here, in mammary epithelial cells. Data in these systems
and those presented here have implicated BCL2 as a
common effector, although probably not the only one.
Whether the other ‘MYB phenotypes’ of proliferation
and differentiation suppression are mediated by com-
mon or specific factors needs to be elucidated. However,
it is likely that some tissue-specific factors are involved
in effects on differentiation, and indeed this is supported
by our recent data in the haemopoietic system (Zhao et
al: Defining the MYB Transcriptional Program by Gen-
ome-Wide Chromatin Occupancy and Expression Ana-
lyses, submitted).
Targeting MYB in breast cancer
As discussed above, our data [19] (and that reported
here) imply that MYB is required in ER positive mam-
mary carcinoma cells for three key ‘hallmarks of cancer’
[58] - continued proliferation, suppression of differentia-
tion, and resistance to apoptosis. This could potentially
make MYB an excellent therapeutic target in breast can-
cer, particularly under conditions where MYB activity is
limiting for one or more of these processes. The attrac-
tiveness of MYB as a target in this disease is reinforced
by the fact that 60 to 70% of all human breast tumors
express MYB [17,19] (see also [6,19,59]).
Treating tumors by inducing cancer cell differentiation
has been discussed for some time; although an attractive
concept, it has rarely proved to be an effective approach
by itself. However, the combination of DIAs and other
agents can be highly effective; for example, the combina-
tion of the DIA all-trans retinoic acid with arsenic triox-
ide is now the accepted treatment modality for patients
with acute promyelocytic leukemia [60]. Our studies have
identified the combination of MYB inhibition with DIA
treatment as a potentially effective combination therapy
for ER positive breast cancer that not only suppresses
proliferation but induces extensive tumor cell death.
Further development will require the identification of
more appropriate DIAs for clinical use, and of a feasible
approach for inhibiting MYB activity in breast tumors.
The studies shown here together with our unpublished
work suggest that VES and HDIs are both good candidate
DIAs for clinical use. Importantly, both have been used
in patients and, indeed, the HDI SAHA/Vorinistat is
approved for treating cutaneous T-cell lymphoma.
Our observation that fulvestrant, which is in clinical
use for breast cancer treatment, appears to substitute
in this regard for MYB knockdown suggests that the
combination of this agent with clinically acceptable
DIAs might be one approach to bring this approach to
clinical application. This is in apparent contradiction
w i t ht h ed a t af r o mD el o sS a n t o set al. [61], which
showed that 2.5 mM NaBu induced about 60% of
MCF-7 cells to undergo apoptosis, and that there was
no synergistic effect of adding fulvestrant. It must be
pointed out that the experiments of De los Santos et
al. were carried out in under estrogen-free conditions.
It is likely that the addition of an anti-estrogenic com-
pound would not synergize with a histone deactetylase
inhibitor in an already estrogen-free environment. This
is further strengthened by the studies by Chopin et al
[62], which show less than 20% of MCF-7 s cells are
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complete (i.e. not estrogen-free) medium. It seems,
therefore, that there is clear evidence for a potential
chemotherapeutic effect of combining a suitable anti-
estrogen and a DIA.
Although we have discussed a number of approaches to
targeting MYB itself in breast cancer [59], it may instead
be possible to target specifically the anti-apoptotic effec-
tors of MYB to induce tumor cell killing by DIAs. Our
data show that BCL2 is a relevant MYB target in this
regard, raising the possibility of using recently-developed
inhibitors of BCL2 [63], such as ABT-737 [64] and its
more bioavailable analogue ABT-263 [65], in combina-
tion with DIAs. Interestingly, such a combination has
recently shown efficacy in a mouse lymphoma model
[66]. Further laboratory and animal model studies to
assess the effectiveness and potential toxicities of these
approaches in vitro and in vivo are clearly warranted.
Conclusions
This study has shown that MYB knockdown sensitizes
breast cancer cells to induced differentiation and apop-
tosis. Conversely, ectopic MYB expression blocks
induced growth arrest and differentiation of BC cells.
Furthermore, ectopic MYB expression blocks apoptosis
of breast cancer cells by directly upregulating BCL2.
These data highlight the potential of combining differ-
entiation inducers and MYB inhibition to lead to new
breast cancer therapies.
Additional material
Additional file 1: Differentiation induction of MCF-7 cells treated
with the DIAs VES or TPA. MCF-7 cells were grown on glass cover slips
and treated with increasing amounts of (a) vitamin E succinate (VES) or
(b) 12-O-tetradecanoylphorbol-13-acetate (TPA), as indicated, for 72
hours. Fluorescence microscopy (×63) was used to detect. differentiation
as assessed by Nile Red staining for lipid vesicles (red). Nuclear DNA was
stained with DAPI (blue). (c to e) Cell cycle analysis of MCF-7 cells
treated with three differentiation-inducing agents (as indicated) at
different doses (also as indicated) for 72 hours. Cells were fixed, stained
with propidium iodide and analyzed by flow cytometry. The percentage
of cells in each cell cycle phase was determined using ModFit.
Additional file 2: The effect of MYB knockdown on differentiation in
MCF-7 cells. (a). MCF-7 cells stably transduced with a doxycycline (Dox)-
inducible lentiviral siRNA, were grown with or without Dox for 72 hours.
The cells were then stained for lipid droplet (Nile Red - Red) or nuclear
DNA (DAPI - blue), and evaluated by fluorescent microscopy (×63) or (b)
Flow cytometry; data for control cell lines are also shown. (c)
Quantitative PCR analysis of ß-casein mRNA levels following Dox
treatment. Data are normalised against untreated cells.
Additional file 3: The effect of MYB knockdown on differentiation in
ZR-75-1 cells. (a) ZR-75-1 cells stably transduced with a doxycycline
(Dox)-inducible lentiviral siRNA, were grown with or without Dox for 72
hours. The cells were then stained for lipid droplet (Nile Red - Red) or
nuclear DNA (DAPI - blue), and evaluated by fluorescent microscopy
(×63) or (b) Flow cytometry; data for control cell lines are also shown. (c)
Quantitative PCR analysis of ß-casein mRNA levels following Dox
treatment. Data are normalised against untreated cells.
Additional file 4: MYB knockdown sensitises ZR-75-1 cells to the
differentiation-inducing agent NaBu. (a) ZR-75-1 cells with a
doxycycline (Dox)-inducible shRNA targeting MYB [19] were grown on a
glass coverslip, treated with or without 5 μg/mL Dox for 24 hours before
exposure to the indicated concentrations of sodium butyrate (NaBu) for
three days. They were then stained with Nile Red (red) for lipid vesicles
and DAPI (blue) for DNA detection. (b) Flow cytometric analysis of
TUNEL staining for apoptotic cells. ZR-75-1 cells stably transfected with
inducible shRNA treated for 24 hours with or without Dox, were grown
in the presence or absence of 1 mM NaBu for a further 24 hours, and
were then assayed for apoptosis using TUNEL. Standard deviation is
represented by error bars.
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